| |
|
|
iCORD(Cord Blood Bank)’s Proprietary Technology
CHA Biotech accumulates the top-notch technologies of stem cells, which are key areas of future medicine in the 21st century,
by continually conducting integrated research on incurable disease, embryonic stem cell, and adult stem cell,
and developing
related source technologies.
With its abundant clinical experiences and investigations, CHA Biotech is making a ‘healthy life of mankind’ a reality
through
cord blood banking business, which is a key to regenerative medicine.
One Stop Bio∙Medical Complex System
CHA Biotech possess capability to perform one-stop service from Cord Blood Storage to Transplantation to Treatment through
Industry-Academic-Research- Hospital Collaboration’ Cluster of CHA Medical Group.
Financial Stability
CHA Biotech has an overwhelming amount of consolidated total assets and is equipped with the largest cord blood
storage facility
located at CHA Bio Complex among other family cord blood banks in Korea.
|
What is Cord Blood? A key to Regenerative Medicine?
Mesenchymal Stem Cell
 Cells with ability to self-replicate, immune-control and differentiate into
various human tissues including kidney, brain, nerve, and muscle
Applied in clinical research of various incurable diseases and in the
development of stem cell treatments
|
|
It is blood in the umbilical cord that fetus and mother are connected
and a ‘life source’ that contains large amount of hematopoietic
stem cells(immune cells) and mesenchymal stem cells.
 Total Nucleated Cells(TNC) that are Separated, Processed,
and Stored
from Cord Blood
Hematopoietic Stem Cell
Mother cell that exists in cord blood, bone marrow, and peripheral blood,
and produces
blood cells(immune cells) through proliferation and differentiation
Transplantation used for various incurable diseases such as hematologic
malignancies
(diseases)
Immunocyte
Cells with ability to resist, destroy, and heal cancer cells, toxins, and pathogens
that have
invaded in the body Types of Immunocytes: NK Cell, T Lymphocyte,
B Lymphocyte, etc.
Applied in development of 3rd generation cancer immunotherapies
|
Curable Diseases
| |
Diseases currently in Clinical Trial
Cerebral Palsy, Development Delay Disability,
Type 1 Diabetes, Autism, etc.
|
|
|
Utility Value in Future
When the efficacy of cord blood is fully secured through many
clinical trials according to future technological developments,
Autologous or Family Cord Blood can be utilized as stem cell
therapy or immunotherapy products for specific target diseases.
|
|
|